Ontvang nu dagelijks onze kooptips!
spineway so kansrijke pennystocker parijs
En intussen naar 0,0007/0,0008 - het aantal nullen achter de komma is bijna niet te tellen :-)
Dus mijn positie vanmorgen verdubbeld, want de daghandeltrein zal dit station vroeger of later wel weer eens aandoen, ondanks OCABSA, of misschien wel dank zij OCABSA.
Benieuwd naar deze cijfers...
January 18, 2022 after market closing
Publication of 2021 turnover
Press Release Ecully, 18 January, 2021 – 6 pm
Revenue increased by 27% in 2021 to €4.3 M Q4 2021 superior to Q4 2020 (+ 26%)
In thousands of euros
*Figures not audited including revenue from Distimp since its acquisition date, i.e., from 26 June 2021 through 31 December 2021, representing 365 k€.
In a context still disrupted by the pandemic, Spineway closes the 2021 financial year with a turnover of €4.3 million, up 27% compared to 2020, driven by a strong commercial dynamic concretized by a 4th quarter at €1.3 million, up 26% compared to last year.
This growth was driven in particular by high sales performances in the Group's historical areas. Thus, Latin America recorded revenues of nearly €2 million, up 33% compared to fiscal year 2020, despite a still complicated situation; while sales in Asia reached €1 million, up 19% compared to 2020.
Moreover, in line with its strategy, Spineway is continuing to develop its product mix by strengthening its higher value-added ranges. Thus, benefiting from the first commercial synergies with Distimp, sales in Europe amounted to nearly €1 million, up 38% compared to last year.
The financial situation remains very solid and reinforces the Group's capacity to accelerate its development through investments.
After a strong fourth quarter, Spineway is pursuing its strategic plan combining organic and external growth with the ambition of becoming a leading European player with premium positioning in spine surgery.
SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com
This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.
Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports. Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).
ISIN: FR0011398874 - ALSPW
Gaat lekker, zo :-)
Wordt lachen, als ze ooit naar 0,01 gaan.
End January, 2022
Publication of 2021 annual results
Press Release Ecully, April 15, 2022 – 10 am
Continued growth in Q1 2022
Q1 2022 revenues up +55%
In thousands of euros 2022* 2021 % Variation
Turnover Q1 1 342 865 + 55%
Unaudited consolidated data
In line with the last quarter of 2021, Spineway confirms its growth momentum and totals revenues
of €1.3 million for the first quarter of 2022, up 55% compared to the year 2021. The latter benefits
from the synergies implemented with Distimp, the growth of sales in France and positive
commercial orientation in Latin America.
Sales in Latin America showed strong growth of 31.1% compared to 2021 and represented 41.5% of
Group sales (€558 k). Despite the continuing health crisis in the territory, the region is benefiting
from a return to a more normalized situation in surgical activity, which has enabled the booking of
The significant growth in the Europe region, which doubled compared to Q1 2021 to reach €427 k,
was mainly driven by sales in France, which now represent 26.2% of Group sales at €351 k in Q1
2022, following the successful integration of Distimp.
Asia remained stable in Q1 2022 (€181 k), while the Middle East zone amounted to €176 k and
increased significantly compared to Q1 2021, following the strengthening of the Group's presence in
On the basis of the upward trend at the beginning of 2022, Spineway confirms the recovery of its
business and reinforces its ambition to become a leading European player in spine surgery with
Direct naar Forum